The FDA has issued an emergency use authorization (EUA) that would allow the use of the Centers for Disease Control and Prevention’s (CDC) 2019-nCoV Real-Time RT-PCR Diagnostic Panel by any CDC-qualified lab across the US.
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has released an updated version of the child and adolescent immunization schedule for ages 18 years and younger in the United States.
A recent report published in the New England Journal of Medicine describes the case of a 57-year-old male patient who developed skin hyperpigmentation following chemotherapy that included fluorouracil.
As of February 3, 2020, there are 11 confirmed cases of 2019 novel coronavirus (2019-nCov) in the US, according to the Centers for Disease Control and Prevention.
A recent report published in the New England Journal of Medicine describes the case of a patient with persistent skin discoloration associated with the use of the antiarrhythmic agent amiodarone.
Amzeeq topical foam 4% will soon be available (January 13, 2020) by prescription for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older.
The FDA has approved RediTrex (methotrexate injection; Cumberland) for the management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis, who are intolerant of or had an inadequate response to first-line therapy.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for clascoterone cream 1% for the treatment of acne.
Rituximab was found to be superior to mycophenolate mofetil (MMF) in adult patients with severe pemphigus vulgaris, according to new phase 3 trial data.
Severe micronutrient deficiency should be considered in the differential diagnosis in complex cases where a clear etiology is unknown.
